Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Do analysts prefer SUPN or JAZZ?

Supernus Pharmaceuticals currently has a consensus target price of $43.00, indicating a potential downside of 2.25%. Jazz Pharmaceuticals has a consensus target price of $178.67, indicating a potential upside of 42.68%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.88

Is SUPN or JAZZ more profitable?

Supernus Pharmaceuticals has a net margin of 9.70% compared to Jazz Pharmaceuticals' net margin of -9.91%. Supernus Pharmaceuticals' return on equity of 14.22% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	9.70%	14.22%	10.82%
Jazz Pharmaceuticals	-9.91%	5.02%	1.73%

Do institutionals and insiders have more ownership in SUPN or JAZZ?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media refer more to SUPN or JAZZ?

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 20 mentions for Jazz Pharmaceuticals and 13 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.37 beat Supernus Pharmaceuticals' score of 0.64 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	15 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has preferable earnings & valuation, SUPN or JAZZ?

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$661.82M	3.73	$73.86M	$1.15	38.25
Jazz Pharmaceuticals	$4.07B	1.87	$560.12M	-$6.73	-18.61

Which has more volatility and risk, SUPN or JAZZ?

Supernus Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Summary

Supernus Pharmaceuticals and Jazz Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.